Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지

Relationship between Expression of XIAP Protein in Operable Non-small Cell Lung Carcinomas and Apoptosis Index and Postoperative Prognosis

비소세포폐암조직에서 XIAP 발현과 고사지수 및 수술 후 예후와의 관계

  • Kim, Sang Hyun (Department of Internal Medicine, Dong Eui Hospital) ;
  • Lee, Chang Hun (Department of Pathology, Pusan National University College of Medicine) ;
  • Sol, Mee Young (Department of Pathology, Pusan National University College of Medicine) ;
  • Song, Jin Mi (Department of Pathology, Pusan National University College of Medicine) ;
  • Lee, Jong Hyub (Department of Internal Medicine, Dong Eui Hospital) ;
  • Lee, Min Ki (Department of Internal Medicine, Pusan National University College of Medicine) ;
  • Kim, Jong Min (Department of Anatomy, Dong-A University College of Medicine)
  • 김상현 (동의병원 내과) ;
  • 이창훈 (부산대학교 의과대학 병리학교실) ;
  • 설미영 (부산대학교 의과대학 병리학교실) ;
  • 송진미 (부산대학교 의과대학 병리학교실) ;
  • 이종협 (동의병원 내과) ;
  • 이민기 (부산대학교 의과대학 내과학교실) ;
  • 김종민 (동아대학교 의과대학 해부학교실)
  • Received : 2005.02.14
  • Accepted : 2005.05.04
  • Published : 2005.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background : Dysregulation of apoptosis plays an important role in carcinogenesis, tumor progression, and resistance to chemotherapy. X-linked inhibitor of apoptosis (XIAP) is considered to be the most potent caspase inhibitor of all known IAP (inhibitor of apoptosis) family members. This study was designed to assess the pattern of expression and the prognostic value of XIAP in radically resected non-small cell lung carcinoma (NSCLC) patients. Method : The expression of XIAP and its relationship with clinicopathologic parameters (patient age, TNM stage, TNM-pT, TNM-pN, histologic type, VEGF expression, microvessel density, PCNA index) and overall survival were analysed with formalin-fixed, paraffin-embedded blocks from eighty cases of NSCLC. In addition, the apoptotic index (AI) was also assessed. Results : In a regard to histologic type, squamous cell carcinoma (SCC) showed XIAP expression in 91.3%(42/46) and adenocarcinoma (AC) in 61.8%(21/34). The difference was significant(p=0.001). There was no correlation between XIAP expression and other parameters. In the group of AC, XIAP expression showed the signifcant correlation with older age group ${\geq}58years$ and VEGF expression(p=0.028, p=0.014, respectively). The AI in the group with or without XIAP expression were $2.5{\pm}4.9%$ and $18.5{\pm}28.9%$, respectively(p=0.001). Both groups just aforementioned showed no significant difference in median survival time (42.5 months, 29.8 months, respectively). Conclusion : This study suggests that the XIAP expression in NSCLCs could have relation to inhibition of apoptosis, and show differential expression according to histologic type. However, its prognostic role during the progression of NSCLC needs to be further defined.

연구 배경 : 세포자멸사의 장애는 발암, 암의 진행, 화학치료시 내성 등에 중요한 역할을 한다. XIAP는 IAP군 중에 가장 강력한 caspase 억제제로 알려져 있다. 본 연구는 비소세포폐암에서 XIAP의 면역조직화학적 발현이 종양진행이 환자생존율에 미치는 영향을 확인해 보고자 시행되었다. 방 법 : 수술적 절제가 시행된 80예의 비소세포 폐암종의 조직에서 XIAP의 면역 조직학적 발현을 조사하여 임상병리학적 인자들[환자의 연령, TNM 병기, TNMpT, TNM-pN, VEGF, microvessel density(MVD), PCNA index, apoptotic index (AI)]과 생존율과의 연관을 분석하였다. 결 과 : 편평세포암종 46예 중 42예(91.3%)에서, 샘암종 34예 중 21예(61.8%)에서 양성을 보여 종양의 조직형별 비교시 편평세포암종은 샘암종에 비해 유의하게 높은 XIAP의 발현을 보였다(p=0.001). 각 조직형내에서 비교시 샘암종의 경우 XIAP는 58세이상의 고 연령군 및 VEGF의 발현과 유의한 상관관계를 보였지만(p=0.028, p=0.014, respectively) 편평세포암종의 경우 XIAP는 모든 임상병리학적 인자들과 상관관계를 보이지 않았다. TUNEL 염색으로 결정된 AI는 XIAP 양성군이 $2.5{\pm}4.9%$, XIAP 음성군이 $18.5{\pm}28.9%$로서 후자에서 유의하게 높은 수치를 보였다(p=0.001). AI는 XIAP를 제외한 다른 임상병리학적 인자들과는 상관관계를 보이지 않았다. 생존 여부의 확인이 가능했던 72예에서 XIAP 음성군의 중앙 생존기간은 29.89개월, XIAP 양성군의 중앙 생존기간은 42.5개월로서, 후자에서 술 후 생존 기간은 더 길었지만 통계학적 차이를 보이지는 않았다. 결 론 : 비소세포폐암종에서 XIAP는 종양의 조직형, 특히 편평세포암종에서 높은 발현과, 종양의 AI와 역의 상관관계를 보였다. 그러나 XIAP의 발현이 임상병리학적 예후인자들 및 생존율과 유의한 관련성을 보이지 않은 것은 생체 조직에서 XIAP의 생물학적 역할은 매우 복잡할 수 있다는 것을 암시하므로 향후 이의 생물학적 역할과 관련 물질들에 대한 연구가 좀 더 진행되어야 할 것으로 사료된다.

Keywords

References

  1. Kim HK. Lung cancer in Korea. Cancer Res Treat　2002;34:1-2 https://doi.org/10.4143/crt.2002.34.1.1
  2. Lee CT. Epidemiology of lung cancer in Korea. Cancer Res Treat 2002;34:3-5 https://doi.org/10.4143/crt.2002.34.1.3
  3. Poleri C, Morero JL, Nieva B, Vazquez MF, Rodriquez C, de Titto E, et al. Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma. Chest 2003;123:1858-67 https://doi.org/10.1378/chest.123.6.1858
  4. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21:485-95 https://doi.org/10.1093/carcin/21.3.485
  5. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941-53 https://doi.org/10.1200/JCO.1999.17.9.2941
  6. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002;3:401-10 https://doi.org/10.1038/nrm830
  7. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J 1999;18: 5242-51 https://doi.org/10.1093/emboj/18.19.5242
  8. Duckett CS, Li F, Wang Y, Tomaselli KJ, Thompson CB, Armstrong RC. Human IAP-like protein regulates programmed cell death downstream of Bcl-xL and cytochrome C. Mol Cell Biol 1998;18:608-15 https://doi.org/10.1128/MCB.18.1.608
  9. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998;152:43-9
  10. Monzo M, Rosell R, Felip E, Astudillo J, Sanchez JJ, Maestre J, et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA is a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999;17:2100-4 https://doi.org/10.1200/JCO.1999.17.7.2100
  11. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000;6:1796-803
  12. Liu SS, Tsang BK, Cheung AN, Xue WC, Cheng DK, Ng TY, et al. Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur J Cancer 2001;37:1104-10 https://doi.org/10.1016/S0959-8049(01)00085-5
  13. Ferreira CG, van der Valk P, Span SW, Ludwig I, Smit EF, Kruyt FA, et al. Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res 2001;7:2468-74
  14. Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996;73:931-4 https://doi.org/10.1038/bjc.1996.166
  15. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8 https://doi.org/10.1056/NEJM199101033240101
  16. Duckett CS, Nava VE, Gedrich RW, Clem RJ, van Dongen JL, Gilfillan MC, et al. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J 1996;15:2685-94
  17. Takeuchi M, Rothe M, Goeddel DV. Anatomy of TRAF2: distinct domains for nuclear factor-kappaB activation and association with tumor necrosis factor signaling proteins. J Biol Chem 1996;271:19935-42 https://doi.org/10.1074/jbc.271.33.19935
  18. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-4
  19. Kappler M, Kohler T, Kampf C, Diestelkotter P, Wurl P, Schmitz M, et al. Increased survivin transcript levels: an independent negative predictor of survival in soft tissue sarcoma patients. Int J Cancer 2001;95:360-3 https://doi.org/10.1002/1097-0215(20011120)95:6<360::AID-IJC1063>3.0.CO;2-1
  20. Hofmann HS, Simm A, Hammer A, Silber RE, Bartling B. Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. J Cancer Res Clin Oncol 2002;128:554-60 https://doi.org/10.1007/s00432-002-0364-z
  21. Nor JE, Christensen J, Mooney DJ, Polverini PJ. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999;154:375-84 https://doi.org/10.1016/S0002-9440(10)65284-4
  22. Duarte IG, Bufkin BL, Pennington MF, Gal AA, Cohen C, Kosinski AS, et al. Angiogenesis as a predictor of survival after surgical resection for stage non-small-cell lung cancer. J Thorac Cardiovasc Surg 1998;115:652-8 https://doi.org/10.1016/S0022-5223(98)70331-9
  23. Teppo L, Salminen E, Pukkala E. Risk of a new primary cancer among patients with lung cancer of different histological types. Eur J Cancer 2001;37:613-9 https://doi.org/10.1016/S0959-8049(00)00428-7
  24. Komaki R, Fujii T, Perkins P, Ro JY, Allen PK, Mason KA, et al. Apoptosis and mitosis as prognostic factors in pathologically staged N1 nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1996;36:601-5 https://doi.org/10.1016/S0360-3016(96)00351-3
  25. Tanaka F, Kawano Y, Li M, Takata T, Miyahara R, Yanagihara K, et al. Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer. J Clin Oncol 1999;17:2728-36 https://doi.org/10.1200/JCO.1999.17.9.2728